| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5599300 | Atherosclerosis | 2017 | 22 Pages |
Abstract
In conclusion, HHcy is an independent risk factor for PAD in the Chinese Han population. A prospective and randomized clinical trial of homocysteine lowering therapy in the Chinese population is needed to assess the causal nature of the relationship.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Dan Rong, Jie Liu, Xin Jia, Daniah AL-Nafisee, Senhao Jia, Guoyi Sun, Yue Li, Weihang Lu, Haifeng Li, Hongpeng Zhang, Xiaohui Ma, Jiang Xiong, Xiaoping Liu, Raouf A. Khalil, Wei Guo,